BridgeBio Pharma (BBIO) Stock Price, News & Analysis

Company Overview

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Key Stats

• Today's Range: $25.14 to $26.05
• 50-Day Range: $23.91 to $31.30
• 52-Week Range: $21.62 to $44.32
• Volume: 1.43 million shs
• Average Volume: 1.88 million shs
• Market Capitalization: $4.72 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $47.92
• Consensus Rating: Moderate Buy

BridgeBio Pharma Stock Analysis - MarketRank™

BridgeBio Pharma scored higher than 91% of companies evaluated by MarketBeat, and ranked 108th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BridgeBio Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

BridgeBio Pharma has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for BridgeBio Pharma are expected to decrease in the coming year, from ($2.54) to ($3.10) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BridgeBio Pharma is -7.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BridgeBio Pharma is -7.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.35% of the float of BridgeBio Pharma has been sold short.

Short Interest Ratio / Days to Cover

BridgeBio Pharma has a short interest ratio ("days to cover") of 8.9.

Change versus previous month

Short interest in BridgeBio Pharma has recently increased by 10.73%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BridgeBio Pharma does not currently pay a dividend.

Dividend Growth

BridgeBio Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -2.31

Percentage of Shares Shorted

13.35% of the float of BridgeBio Pharma has been sold short.

Short Interest Ratio / Days to Cover

BridgeBio Pharma has a short interest ratio ("days to cover") of 8.9.

Change versus previous month

Short interest in BridgeBio Pharma has recently increased by 10.73%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.66

News Sentiment

BridgeBio Pharma has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for BridgeBio Pharma this week, compared to 6 articles on an average week.

Search Interest

Only 7 people have searched for BBIO on MarketBeat in the last 30 days. This is a decrease of -59% compared to the previous 30 days.

MarketBeat Follows

4 people have added BridgeBio Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BridgeBio Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $150,128,821.00 in company stock.

Percentage Held by Insiders

24.66% of the stock of BridgeBio Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

99.85% of the stock of BridgeBio Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BBIO Stock Analysis - Frequently Asked Questions

How have BBIO shares performed this year?

BridgeBio Pharma's stock was trading at $40.37 at the beginning of 2024. Since then, BBIO stock has decreased by 37.5% and is now trading at $25.23.
View the best growth stocks for 2024 here.

How were BridgeBio Pharma's earnings last quarter?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) released its quarterly earnings data on Thursday, August, 1st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.61. The company's revenue for the quarter was up 32.1% compared to the same quarter last year.

When did BridgeBio Pharma IPO?

BridgeBio Pharma (BBIO) raised $225 million in an initial public offering on Thursday, June 27th 2019. The company issued 15,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR served as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.

How do I buy shares of BridgeBio Pharma?

Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of BridgeBio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BridgeBio Pharma investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Pfizer (PFE), Roku (ROKU) and Editas Medicine (EDIT).

Company Calendar

• Last Earnings: 8/01/2024
• Today: 10/05/2024
• Next Earnings (Estimated): 11/07/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BBIO
• CUSIP: N/A
• CIK: 1743881
• Web: bridgebio.com
• Phone: (650) 391-9740
• Fax: N/A
• Employees: 400
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $47.92
• High Stock Price Target: $70.00
• Low Stock Price Target: $37.00
• Potential Upside/Downside: +89.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 13 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-643,200,000.00
• Net Margins: -207.11%
• Pretax Margin: -210.62%
• Return on Equity: N/A
• Return on Assets: -76.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.59
• Quick Ratio: 4.59

Sales & Book Value

• Annual Sales: $219.12 million
• Price / Sales: 21.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($7.72) per share
• Price / Book: -3.27

Miscellaneous

• Outstanding Shares: 187,129,000
• Free Float: 140,983,000
• Market Cap: $4.72 billion
• Optionable: Optionable
• Beta: 1.08